A Talk by John L. Marshall
Chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, Washington DC, USA
About this talk
John L. Marshall, MD Director, The Ruesch Center for the Cure of GI Cancers Frederick P. Smith Endowed Chair Chief, Hematology and Oncology Lombardi Comprehensive Cancer Center Georgetown University Medical Center
Over the last decade, we have seen a dramatic change in our understanding of cancer biology. As a result, we are increasingly relying on precision medicine to drive new therapeutics and have seen significant improvements in cancer outcomes. Accompanying this dramatic shift are significant changes in practice patterns involving molecular testing and the economic impact on our cancer healthcare systems. The last decade began with a standard of care of occasional single genetic tests being done in specific clinical scenarios. We ended the decade with an increasing standard for broad molecular testing in a high percentage of our patients with metastatic disease. Looking toward the decade ahead, we not only expand our use of broad molecular testing but we will shift towards multi-omic testing requiring the application of artificial intelligence to assist in our decision making.
